MANTOVANI, GIOVANNI
 Distribuzione geografica
Continente #
EU - Europa 29.200
NA - Nord America 2.610
AS - Asia 443
SA - Sud America 4
AF - Africa 1
OC - Oceania 1
Totale 32.259
Nazione #
IT - Italia 28.459
US - Stati Uniti d'America 2.594
CN - Cina 302
UA - Ucraina 263
SE - Svezia 189
DE - Germania 80
GB - Regno Unito 77
SG - Singapore 68
FI - Finlandia 63
KR - Corea 35
IN - India 26
FR - Francia 25
CA - Canada 16
BE - Belgio 15
ES - Italia 8
RU - Federazione Russa 6
IR - Iran 5
NL - Olanda 5
JP - Giappone 4
BO - Bolivia 2
IE - Irlanda 2
PT - Portogallo 2
RO - Romania 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
EC - Ecuador 1
GR - Grecia 1
HK - Hong Kong 1
KZ - Kazakistan 1
MU - Mauritius 1
PL - Polonia 1
TW - Taiwan 1
Totale 32.259
Città #
Cagliari 28.290
Fairfield 399
Woodbridge 260
Chandler 223
Ashburn 208
Houston 196
Seattle 180
Nyköping 177
Wilmington 150
Ann Arbor 148
Jacksonville 148
Cambridge 146
Dearborn 64
Shanghai 52
Boardman 51
Nanjing 46
Boston 44
Singapore 39
Beijing 38
Guangzhou 30
Seoul 28
Helsinki 22
Pune 21
San Diego 21
New York 20
Changsha 18
Brussels 15
London 15
Shenyang 15
Toronto 15
Nanchang 12
Jiaxing 10
Milan 10
Rome 10
Redwood City 9
Tianjin 9
Norwalk 8
Jinan 7
Orange 7
San Mateo 7
Hangzhou 6
Kunming 6
Los Angeles 6
Verona 6
Auburn Hills 5
Barcelona 5
Brandizzo 5
Hebei 5
Hefei 5
Sassari 5
Augusta 4
Kilburn 4
Mountain View 4
Somma Vesuviana 4
Torino 4
Amsterdam 3
Chicago 3
Detroit 3
Islington 3
Leawood 3
Monmouth Junction 3
Ningbo 3
Salerno 3
Wuhan 3
Acton 2
Cerignola 2
Chiswick 2
Chuncheon 2
Cosenza 2
Costa Masnaga 2
Costa Mesa 2
Dublin 2
Fuzhou 2
Harbin 2
Manitou Springs 2
Muenster 2
Qingdao 2
Redmond 2
Reggello 2
San Giorgio in Bosco 2
Santa Cruz 2
Sobrado de Paiva 2
Sordio 2
Tonara 2
Valencia 2
Vitulazio 2
Washington 2
Xian 2
Yazd 2
York 2
Zhengzhou 2
Almaty 1
Arcevia 1
Ardabil 1
Ariano Irpino 1
Buenos Aires 1
Calasetta 1
Camaiore 1
Catania 1
Cedar Knolls 1
Totale 31.332
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.296
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.067
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 1.906
Advances in pharmacologic strategies for cancer cachexia 1.747
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1.586
The nutritional risk in oncology: a study of 1,453 cancer outpatients 1.535
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 1.426
null 936
null 819
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response 800
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 788
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 782
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients 751
Current medications for cancer cachexia 740
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer 706
null 681
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 623
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 613
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 590
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2 578
null 529
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 461
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 433
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation 406
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate 405
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 396
Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient = Efficacia, applicabilità e significato prognostico di una valutazione geriatrica multidimensionale nel paziente oncologico anziano 387
Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexial/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 382
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 381
Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients 366
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation 363
Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches = Ruolo delle citochine infiammatorie e della leptina nell'anoressia/cachessia neoplastica. Aspetti metabolici e terapeutici 358
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: A tentative quantitative evaluation of organ preservation and clinical response 352
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients 352
Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect 350
Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions 338
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 332
Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokynes 325
Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: Larynx preservation and clinical response 312
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) 276
Anorexia/Cachexia and oxidative stress in cancer patients = Anoressia/Cachessia e stress ossidativo nei pazienti con cancro 254
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC 212
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 181
Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer 170
Medroxyprogesterone acetate reduces the In vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 123
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies 118
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies 105
[p55 and p75 subunits of the IL 2 receptor, membrane bound and soluble, in peripheral lymphocytes in patients with solid tumors] 100
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy 98
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial 89
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin 82
Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients 73
Preovulatory human follicular fluid in vitro inhibits interleukin (IL)- 1α, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes 67
Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer 64
[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] 59
Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites 57
Evidence that granulosa cells inhibit interleukin-1α and interleukin-2 production from follicular lymphomonocytes 46
Totale 32.372
Categoria #
all - tutte 46.868
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.868


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.947 464 169 64 145 2.252 1.757 848 281 211 138 174 444
2020/20218.504 328 329 436 2.007 1.827 1.184 795 648 139 325 366 120
2021/20221.338 108 100 90 68 156 83 60 89 118 102 158 206
2022/20232.452 183 233 192 173 171 288 70 469 166 148 212 147
2023/20243.617 235 131 130 271 359 655 391 231 200 347 308 359
2024/2025249 249 0 0 0 0 0 0 0 0 0 0 0
Totale 32.372